Glaxo to develop microRNA drugs with Regulus

04/17/2008 | Forbes

Regulus Therapeutics LLC and GlaxoSmithKline have entered into a deal worth up to $600 million to develop new microRNA treatments for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Regulus, a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, sees the deal as an important development in its efforts in microRNA therapeutics, president and CEO Kleanthis Xanthopoulos said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care